76 related articles for article (PubMed ID: 34193567)
21. Comprehensive analysis of pyroptosis-related gene signatures for glioblastoma immune microenvironment and target therapy.
Wang Z; Dai Z; Zhang H; Zhang N; Liang X; Peng L; Zhang J; Liu Z; Peng Y; Cheng Q; Liu Z
Cell Prolif; 2023 Mar; 56(3):e13376. PubMed ID: 36681858
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms.
Karami Fath M; Babakhaniyan K; Anjomrooz M; Jalalifar M; Alizadeh SD; Pourghasem Z; Abbasi Oshagh P; Azargoonjahromi A; Almasi F; Manzoor HZ; Khalesi B; Pourzardosht N; Khalili S; Payandeh Z
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146527
[TBL] [Abstract][Full Text] [Related]
23. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
Chuntova P; Hou Y; Naka R; Yamamichi A; Chen T; Goretsky Y; Hatae R; Nejo T; Kohanbash G; Mende AL; Montoya M; Downey KM; Diebold D; Skinner J; Liang HE; Schwer B; Okada H
Neuro Oncol; 2022 Feb; 24(2):259-272. PubMed ID: 34347086
[TBL] [Abstract][Full Text] [Related]
24. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.
De Waele J; Verhezen T; van der Heijden S; Berneman ZN; Peeters M; Lardon F; Wouters A; Smits ELJM
J Exp Clin Cancer Res; 2021 Jun; 40(1):213. PubMed ID: 34172082
[TBL] [Abstract][Full Text] [Related]
25. IFN-γ- and IL-17-producing CD8
Ohkuri T; Kosaka A; Ikeura M; Salazar AM; Okada H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193567
[TBL] [Abstract][Full Text] [Related]
26. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
27. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
[TBL] [Abstract][Full Text] [Related]
28. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
30. Brain tumor immunotherapy with type-1 polarizing strategies.
Okada H
Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
[TBL] [Abstract][Full Text] [Related]
31. Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Crotty E; Downey K; Ferrerosa L; Flores C; Hegde B; Raskin S; Hwang E; Vitanza N; Okada H
Expert Rev Neurother; 2021 Feb; 21(2):205-219. PubMed ID: 33225764
[TBL] [Abstract][Full Text] [Related]
32. Two subsets of stem-like CD8
Galletti G; De Simone G; Mazza EMC; Puccio S; Mezzanotte C; Bi TM; Davydov AN; Metsger M; Scamardella E; Alvisi G; De Paoli F; Zanon V; Scarpa A; Camisa B; Colombo FS; Anselmo A; Peano C; Polletti S; Mavilio D; Gattinoni L; Boi SK; Youngblood BA; Jones RE; Baird DM; Gostick E; Llewellyn-Lacey S; Ladell K; Price DA; Chudakov DM; Newell EW; Casucci M; Lugli E
Nat Immunol; 2020 Dec; 21(12):1552-1562. PubMed ID: 33046887
[TBL] [Abstract][Full Text] [Related]
33. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
34. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
[TBL] [Abstract][Full Text] [Related]
35. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
Kwok D; Okada H
J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
